drugset
drugset / Trial / NCT00085579

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00085579 ↗

Phase 2 Withdrawn Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab
Open-labelTreatment

Summary

RATIONALE: Interleukin-2 and sargramostim may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: This phase II trial is studying how well giving interleukin-2 together with sargramostim works in treating patients with stage III or stage IV melanoma that was previously treated with chemotherapy.

Timeline

Start
2004-03
Primary completion
2005-03
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic — Subcutaneous
Subject sargramostim Protein / enzyme biologic — Subcutaneous

Indications

cutaneous melanoma